Heart drug gets extended safety check in chinese patients
NCT ID NCT06116968
Summary
This study followed Chinese patients with a heart-thickening condition who had already taken the experimental drug aficamten in an earlier trial. Researchers monitored them for long-term safety and side effects while they continued taking the medication. The goal was to understand how well patients tolerate the drug over time and its effects on heart function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital
Beijing, China
-
Beijing Chao-yang Hospital, Capital Medical University
Beijing, China
-
Fuwai Hospital, CAMS & PUMC
Beijing, China
-
Nanfang Hospital
Guangzhou, China
-
Peking University Third Hospital
Beijing, China
-
Shengjing Hospital of China Medical University
Shenyang, China
-
Sichuan Provincial People's Hospital
Chengdu, China
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
-
The First Hospital of Jilin University
Jilin, China
-
The Second Affiliated Hospital of Nanchang University
Jiangxi, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Conditions
Explore the condition pages connected to this study.